Introduction
Urinary system infections (USI) are mostly caused by Escherichia coli (E.coli) and Klebsiella pneumoniae (K. pneumoniae), which belonging to the family Enterobacteriaceae (1) . In the treatment of USI, antibiotic resistance is a challenging problem. In many USI, the treatment fails due to increased bacterial resistance against antibiotics. Moreover, this resistance may also be increased by the antibiotics used in the treatment (2, 3) . Production of β-Lactamase enzymes is an important mechanism of resistance in Gramnegative bacteria. Many bacterial species such as Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, and Salmonella carry genes that encode ESBL enzymes (4) . β-Lactamase enzymes deactivate the β-Lactam antibiotics by destroying the amide of the β-Lactam ring of the antibiotics. Moreover, these enzymes are synthesized by bacteria via chromosomes, plasmids, or mobile genetic agents known as transposons. Therefore, these enzymes are called extended-spectrum β-Lactamase (ESBL) enzymes (5) . ESBL-mediated resistance exhibits resistance to the antibiotics used in the treatment and may lead to serious treatment failure results and high rates of resistance to ESBL-producing bacteria, especially fluoroquinolones, have been reported. However, carbapenems are highly active in the treatment of these infections (6) . Identification of ESBL-producing E. coli and K. pneumoniae strains and the knowledge of their rates are of prime importance for the selection of an appropriate antibiotics to the treatment of infectious diseases.
In this study, we aimed to investigate the relationship between the ESBL-positive E. coli and K. pneumoniae strains isolated from the urine cultures obtained from the outpatients and the inpatients treated in our clinic and the underlying diseases and also to assess the antibiotic resistance of these isolates.
Material and method
The study included the E. coli and K. pneumoniae strains isolated from the urine cultures obtained from the outpatients and the inpatients treated at Yuzuncu Yil University Dursun Odabas Medical School Urology Clinic between March 2012 and April 2014. The study complies with the Helsinki Declaration. Antibiotic resistance rates, ESBL production, and underlying diseases were retrospectively analyzed. The urinary specimens were plated on blood agar with 5% sheep blood and Eosin-Methylene Blue Agar by quantitative plating method and then incubated at 37 °C for 18-24 h. Subsequently, the bacteria were identified according to conventional methods including colony morphology, gram stains, oxidase test and biochemical tests (indole production, Triple Sugar Iron (TSI) agar, Simmon's Citrate agar, Christensen's Urea agar, and motility test medium). BD Phoenix automated system (Becton Dickinson, USA) was used for further identification of the bacteria that were identified as E. coli and K. pneumoniae and also for assessing their resistance rates and ESBL production. Selection of antibiotics and the resistance rates were evaluated based on the recommendations of the Clinical and Laboratory Standards Institute (CLSI). The results were expressed as mean±SEM. The statistical analysis of the data was carried out with statistical package of social sciences, version 16.0, SPSS Inc, Chicago, Illinois, USA and Graph pad Prism version-5. Statistical comparisons of the rates were performed using the chi-square test and Z test. A 95% confidence interval was used. P values less than 0.05 were considered as statistically significant.
Results
A total of 401 E. coli and 58 K. pneumoniae strains were isolated from the urinary specimens. Of these, 159 (39.6%) of E. coli and 26 (44.8%) of K. pneumoniae strains were ESBL-positive. The most active antibiotics against ESBL-positive E. coli were carbapenems (imipenem, meropenem, and ertapenem), followed by nitrofurantoin, amikacin, and piperacillin/tasobactam, whereas the most active agents against ESBL-positive K. pneumoniae were carbapenems, amikacin, and cefoperason/sulbactam. Table 2 ). In the patients with underlying diseases, the resistance rates against amikacin in the E. coli strains and the resistance rates against ciprofloxacin and trimethoprim/sulfamethoxazole in the K. pneumoniae strains were found statistically significant (p<0.05) ( Table 3) .
Discussion
Recent studies have revealed that there is an increase in the antibiotic resistance in the treatment for urinary system infections in the world (7). This increase is associated with the increase in ESBL-positive bacteria and also with a number of risk factors including length of stay in the intensive care unit, surgical procedures, catheterization period, longer hospital stay, use of cephalosporin and aminoglycoside, and infections caused by ESBL-producing bacteria (8, 9) . ESBL is most commonly found in E. coli and K. pneumoniae strains, and the antibiotics that can be used in the treatment of infections caused by these microorganisms are limited. ESBL-producing strains have been reported by numerous studies in different parts of the world. In multicenter studies, the rates of ESBL-producing bacteria vary between 1-74% depending on the countries and regions (3, 10, 11) . In Turkey, however, the rates of ESBL-positive E. coli and K. pneumoniae strains have been reported between 21-29% and 35-49%, respectively (5, (12) (13) (14) . In our study, we found the rates for E. coli and K. pneumoniae as 39.6% and 44.8%, respectively, which revealed that the rate for E. coli strains was higher than the ones reported for Turkey. This situation could be best explained by the fact that our study only included the urinary samples and the patients who were treated in the urology clinic. Moreover, the high prevalence of underlying diseases (80%) in our (5, 15) . However, the rates we found were slightly higher than the ones reported in the studies. We consider that this situation is associated with the irregular use of antibiotics in the treatment or prophylaxis of urinary system infections. Resistance rates of Piperacillin-Tazobactam in ESBL-producing E. coli and K. pneumoniae strains have been reported between 20-70% (14, 16) . In our study, we found 15.7% for E. Coli and 34.6% for K. pneumoniae strains, both of which were consistent with the rates reported in the literature. Carbapenems are potent antibiotics which possess the broadest spectrum of activity. Carbapenems, such as imipenem and meropenem, are commonly used for the treatment of ESBL-positive and Gram-negative bacterial infections (1, 3, 18) . Resistance rates of carbapenems have been reported between 0-11.1% (1, 18) . In our study, although no resistance was observed against imipenem and meropenem in E. coli and K. pneumoniae strains, the resistance rate of ertapenem was assessed as 1.9% and 3.8%, respectively. Amikacin is the second most active antibiotic following Carbapenems (12, 18) . In our study, the resistance rates of Amikacin in ESBL-positive E. coli and K. pneumoniae strains were 13.2% and 3.8%, respectively. Although the rate in E. coli strains (13.2%) was remarkably high, Amikacin is a useful agent for the treatment of infections caused by ESBL-positive pathogens. We suggest to be carefulness in urological practises because of freguency of urinary system infections. In our study; the most common complicated factors were the presence of recurrence USI for more than 3 times in the preceding year and urological pathology in the urinary system. In this clinical study, neurogenic bladder, BPH, urolithiasis, ureteral obstruction were detected as the most common underlying diseases. ESBL-positive E. coli and K. pneumoniae strains should be kept in mind for the treatment of urinary system infections. Amikacin is one of the most active antibiotics following Carbapenems. Investigation and treatment of underlying diseases is of prime importance. Regional antibiotic resistance rates should be determined and these rates should be kept in mind for the treatment of urinary system infections.
